Abstract
Diabetic retinopathy and glaucoma are major diseases that cause blindness in a high percentage of the population. However, the precise mechanisms involved in the onset and the progression of these diseases are still not completely known. Recent studies have shown that there appears to be an association between these two disease processes because the incidence of glaucoma is higher in diabetic patients than in non-diabetic patients. To reduce the number of patients with vision loss from these diseases, new therapeutic strategies must be established to prevent the development and the progression of these diseases. In this report, we focus on the biochemical links between diabetic retinopathy and glaucoma, viz., an overexpression of extracellular matrix and death of retinal ganglion cells. To establish new therapeutic strategies for both diseases, the biochemical links between diabetic retinopathy and glaucoma and an identification of the factors that are common to the pathogenesis of both diseases, must be determined. In addition, the potential use of gene therapies including antisense oligonucleotides and small interference RNAs should be considered for both diseases. We expect that with the advent of new therapies, a larger number of patients with diabetic retinopathy and/or glaucoma will be cured.
Keywords: Diabetic retinopathy, glaucoma, extracellular matrix, retinal ganglion cell death, antisense oligonucleotides, small interference RNA
Current Drug Therapy
Title: Common Therapeutic Strategies for Diabetic Retinopathy and Glaucoma
Volume: 2 Issue: 3
Author(s): Toshiyuki Oshitari and Sayon Roy
Affiliation:
Keywords: Diabetic retinopathy, glaucoma, extracellular matrix, retinal ganglion cell death, antisense oligonucleotides, small interference RNA
Abstract: Diabetic retinopathy and glaucoma are major diseases that cause blindness in a high percentage of the population. However, the precise mechanisms involved in the onset and the progression of these diseases are still not completely known. Recent studies have shown that there appears to be an association between these two disease processes because the incidence of glaucoma is higher in diabetic patients than in non-diabetic patients. To reduce the number of patients with vision loss from these diseases, new therapeutic strategies must be established to prevent the development and the progression of these diseases. In this report, we focus on the biochemical links between diabetic retinopathy and glaucoma, viz., an overexpression of extracellular matrix and death of retinal ganglion cells. To establish new therapeutic strategies for both diseases, the biochemical links between diabetic retinopathy and glaucoma and an identification of the factors that are common to the pathogenesis of both diseases, must be determined. In addition, the potential use of gene therapies including antisense oligonucleotides and small interference RNAs should be considered for both diseases. We expect that with the advent of new therapies, a larger number of patients with diabetic retinopathy and/or glaucoma will be cured.
Export Options
About this article
Cite this article as:
Oshitari Toshiyuki and Roy Sayon, Common Therapeutic Strategies for Diabetic Retinopathy and Glaucoma, Current Drug Therapy 2007; 2 (3) . https://dx.doi.org/10.2174/157488507781695685
DOI https://dx.doi.org/10.2174/157488507781695685 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Treatment of the Pulmonary Arterial Hypertension
Current Respiratory Medicine Reviews Inflammation in Cardiovascular Disease and Regulation of the Actin Cytoskeleton in Inflammatory Cells: The Actin Cytoskeleton as a Target
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of Iron Chelation in Cancer Therapy
Current Medicinal Chemistry Biotransformations of Prenylated Hop Flavonoids for Drug Discovery and Production
Current Drug Metabolism Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemokines and Atherosclerotic Plaque Progression: Towards Therapeutic Targeting?
Current Pharmaceutical Design Heart Disease Induced by AAS Abuse, Using Experimental Mice/Rats Models and the Role of Exercise-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry Cardiovascular disease management through restrained inflammatory responses
Current Pharmaceutical Design Glycogen Phosphoprylase (EC 2.4.1.1) Activity During Cardiopulmonary Bypass in Patients Undergoing Cardiac Surgery
Vascular Disease Prevention (Discontinued) Natural Product-Derived Small Molecule Activators of Hypoxia-Inducible Factor-1 (HIF-1)
Current Pharmaceutical Design Drugs and Rhabdomyolysis: From Liver to Kidney
Current Vascular Pharmacology Structural Diversity of Neuritogenic Substances and their Application Perspective
Mini-Reviews in Medicinal Chemistry Proteomic Analysis of the Kidney in Rat Biliary Cirrhosis
Current Proteomics Therapeutic Targeting of Toll-Like Receptors in Gastrointestinal Inflammation
Current Pharmaceutical Design Ischemic Post-Conditioning Partially Reverses Cell Cycle Reactivity Following Ischemia/Reperfusion Injury: A Genome-Wide Survey
CNS & Neurological Disorders - Drug Targets Analysis of Edg-Like LPA Receptor-Ligand Interactions
Current Pharmaceutical Design Up-Regulation of TLR-4 in the Brain After Ischemic Kidney-Induced Encephalopathy in the Rat
CNS & Neurological Disorders - Drug Targets Microcirculation Dysfunction: A Possible Mechanism Responsible for Reverse Redistribution in Myocardial Perfusion Imaging?
Current Medical Imaging The Adiponectin Signaling Pathway as a Novel Pharmacological Target
Mini-Reviews in Medicinal Chemistry